Arbutus ends COVID-19, RNA destabilizer programs after glimpsing preclinical data

2023-09-12
FierceBiotech
临床2期免疫疗法专利侵权siRNA临床1期
An “unfavorable” pharmacokinetic profile in preclinical studies led Arbutus Biopharma to halt its coronavirus efforts.
Arbutus Biopharma has become the latest biotech to exit the COVID-19 space as well as discontinuing its work on RNA destabilizers, tightening its focus on hepatitis B.
Arbutus Biopharmaeline had included AB-343, an oral coronaviCOVID-19apy designed to inhibit the SARS-CoV-2 main protease. Arbutus has also been working on hepatitis Bon therapy that combined AB-343 with a potential nsp12 polymerase inhibitor, but an “unfavorable” pharmacokinetic profile in preclinical studies led the biotech to give up on its coronavirus efforts altogether.
A similar story has played out for AAB-343’ RNA destabilizer, AB-161, which the company also annSARS-CoV-2 main proteaseg Arbutusover “a pre-clinical toxicology finding not related to peripheAB-343uropathy.” AB-161 nsp12 polymerase inhibitore 1 trial for hepatitis B virus, and the company stressed that no safety issues had been reported in the healthy participants of this study.
The company expects the pipeline cuArbutusl extend its cash ruAB-161nto the third quarter of 2025. Arbutus has a number of key readouts lined up before then, including preliminary dataperipheral neuropathyl oAB-161RNAi therapeutic imdusiran in combination with Vaccitech’s antigen-specific immunotherapy VTP-300 in patients with chronic hepatitis B virus. Those initial data are expected in the fourth quarter of this year.
Next up will be preliminary data from a phase 1 trial of oral PD-L1 inhibitor AB-101. While the drug was slapped with a clinical hold by the FDA in April, Arbutus has received the green light to proceed in New Zealand, where it expimdusiraneport data in the first half of next year.VTP-300
CEO William Collier described AB-101 as “highly potent” and saPD-L1 had alreadAB-101onstrated activity against PD-L1 in cells from chronic HBFDAubjects.”
“We … continue to believe thatAB-101point inhibitors may play a role in antiviral immune tolerance in cHBV,” CoPD-L1 added in yesterday’s release.
An FDA hold isn’t the only bump in the road for Arbutus. The company has ongoing lawsuits against Moderna and Pfizer-BioNTech alleging patent infringement of its lipid nanoparticle delivery system. “Document production is currently ongoing in the lawsuit against Moderna with the claim construction hearing scheduled for February 7, 2024,” the biotech said.
DroFDAng its coronavirus and RNA destabilizer programs are only the latest pipeline culls for ArbuModernae company scrapped a phase 1 med in 2019 after two healthy participants fell ill with acute hepatitis, followed less than six months later by axing a precliniModernaatitis B candidate after safety concerns arose in animal studies. In November 2022, the biotech also dropped an oral capsid inhibitor.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。